TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00313313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glyburide
Description: Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
Study: NCT02601235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naridrin
Description: Naridrin® : 2 drops in each nostril once daily as prescription

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afrin
Description: 2 pumps in each nostril every 12 hours.
Study: NCT03392831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripherally inserted central catheter (PICC)
Description: The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheter
Description: The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
Study: NCT02427386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dynamized estrogen
Description: The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
Study: NCT02694276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy
Description: The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
Study: NCT02293252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (Motiva)
Description: interactive bi-directional home telemonitoring system that provides remote monitoring
Study: NCT02527226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial exercises
Description: A series of self-administered facial movements and expressions.
Study: NCT02119195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sealant
Description: resin-based sealant (Clinpro Sealant, 3M ESPE)
Study: NCT03737448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: Subjects with receive up to 60 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: Subjects with receive up to 60 mg daily
Study: NCT04493541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986256 Placebo
Description: Specified Dose on Specified Days
Study: NCT04678037

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROs assessment using sickle cell disease mobile app (SCD-app)
Description: A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROs assessment using sickle cell disease mobile app (SCD-app)
Description: A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
Study: NCT02182024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate low dose
Study: NCT01025791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
Study: NCT02872025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Injected intralesionally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Injected intralesionally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Injected intralesionally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intralesional mRNA 2752
Description: Injected intralesionally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intralesional mRNA 2752
Description: Injected intralesionally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intralesional mRNA 2752
Description: Injected intralesionally
Study: NCT01025791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
Study: NCT02692768

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Live Music Therapy
Description: Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recorded Music Therapy
Description: Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
Study: NCT04068194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy of tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of tumor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO
Study: NCT01003756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative neuromuscular exercise
Description: A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
Study: NCT03295227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04039841

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motor Imagery Test
Description: Imagined Timed Up and Go (iTUG) is the imagined version of the actual Timed Up and Go (rTUG) described above). It is possible to calculate the absolute value of the difference between the time of execution of the TUG imagined and actually executed. This difference is called isochrony index. The alteration of this isochrony index is correlated with the decrease in walking speed during the double task. This test is performed during the osteoporosis screening consultation.~For patients who agree to participate in the FallMI study, the name and contact information of the attending physician will be collected during the same consultation.~Standardised email will be sent to the attending physicians to collect the presence of falls and its consequences. They will be classified as fatal, severe, moderate and inconsequential.
Study: NCT03661359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Determinants of Health Referrals
Description: Patients who screen positive for any of the Social Determinants of Health will be given information for referral to any of the community resources that apply to their situation.
Study: NCT03449940

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed repair

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
Study: NCT02621541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Study: NCT04037449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional analgesia
Description: Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.~Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)
Study: NCT01731158

Intervention type: DRUG
Group type: OTHER
Intervention: Avastin in combination with Roferon-A

Intervention type: DRUG
Group type: OTHER
Intervention: Avastin in combination with Roferon-A

Intervention type: DRUG
Group type: OTHER
Intervention: Afinitor

Intervention type: DRUG
Group type: OTHER
Intervention: Afinitor

Intervention type: DRUG
Group type: OTHER
Intervention: TKI: Sutent, Nexavar or Votrient
Description: TKI

Intervention type: DRUG
Group type: OTHER
Intervention: TKI: Sutent, Nexavar or Votrient
Description: TKI
Study: NCT01234454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
Study: NCT01296893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
Study: NCT05435807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Neuroscience Education
Description: Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Neuroscience Education
Description: Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
Study: NCT02274480

Intervention type: DEVICE
Intervention: cardiac MRI with DWI

Intervention type: DEVICE
Intervention: cardiac MRI with DWI
Study: NCT01650649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine HCl
Description: Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
Study: NCT01025791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.